Organogenesis Holdings (ORGO) Current Deferred Revenue (2025)
Organogenesis Holdings (ORGO) posted quarterly Current Deferred Revenue of $3.9 million for Q4 2025, up 31.06% quarter-over-quarter from $2.9 million in Q3 2025.
Organogenesis Holdings (ORGO) Current Deferred Revenue (2025) Analysis & Trends
Organogenesis Holdings' Current Deferred Revenue history runs 1 years deep, the most recent figure standing at $3.9 million for Q4 2025.
- In Q4 2025, Current Deferred Revenue changed N/A year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (changed N/A YoY), while the FY2025 annual figure was $3.9 million, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $3.9 million, up from $2.9 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $3.9 million in Q4 2025, with the low at $2.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - |
| 10 | Organogenesis Holdings | 240.62 Mn | 193.78 Mn | 20.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.86 Mn |
| Sep 30, 2025 | 2.95 Mn |
| Jun 30, 2025 | 2.68 Mn |